-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
Analysis of the Features ofInnoModels’ADCC Platform
Author:
InnoModels
Release time:
2024-08-01
In the field of biomedicine, antibody-dependent cell-mediated cytotoxicity (ADCC), as a key mechanism in tumor immunotherapy, has always attracted the attention of many researchers. In order to meet the growing research needs, InnoModels Biotechnology (Beijing) Co., Ltd. has successfully built an in vitro pharmacodynamics platform, among which the ADCC platform has won wide recognition in the industry with its unique features and advantages. This article will introduce in detail several major features of InnoModels' ADCC platform.
Diversified experimental service system
InnoModels' ADCC platform is first known for its diversified experimental service system. The platform can support combinatorial experiments on multiple types of tumor cells and immune cells. Whether it is tumor cell lines, primary tumor cells or genetically engineered cell lines, the platform can provide corresponding experimental conditions and technical support. This diversity not only meets the needs of different research projects, but also provides researchers with a wealth of options to choose the most appropriate cell type according to specific research goals.
In terms of effector cells, the platform also supports commercially derived PBMC (peripheral blood mononuclear cells) and clinical patient-derived PBMC. This support allows researchers to get closer to clinical reality and more accurately simulate the immune response process in the human body, thus improving the reliability and practicality of research.
Real simulation environment
In order to more truly reflect the actual situation of the ADCC process, InnoModels Bio's ADCC platform focuses on simulating the in vivo environment. The platform uses advanced cell culture technology and flow cytometry technology to monitor and record changes in cells during the experiment in real time. This technical method not only improves the accuracy of experiments, but also provides researchers with accurate and reliable data support, helping them to understand the details of the ADCC mechanism more deeply.

Highly customizable
InnoModels' ADCC platform is also highly customizable. The platform can customize personalized experimental plans according to the specific needs of researchers, including cell type, drug treatment, experimental time and other aspects. This flexibility enables the platform to meet the diverse needs of different researchers and provides powerful technical support for biomedical research. At the same time, it also avoids the "one size fits all" experimental model and improves the pertinence and efficiency of the research.
Efficient data processing capabilities
In addition to its advantages in experimental design and execution, InnoModels' ADCC platform is also equipped with an advanced data analysis system. This system can automatically process and analyze experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can intuitively understand experimental results through the visual reports provided by the platform, thereby better guiding subsequent research work. This efficient data processing capability not only saves researchers time and energy, but also improves the overall quality and level of research.
Leading technological breakthroughs
InnoModels' innovation in the biomedical field is not only reflected in the ADCC platform, but also includes a series of other leading technological breakthroughs.For example, the company's iHuPDX in vivo drug efficacy model technology, based on xenograft technology of individual patient tumor cells, provides strong support for precision medicine. In addition, InnoModels Biotechnology has also successfully optimized a humanized mouse model of the PBMC immune system, achieving NK reconstruction close to clinical levels, providing a more reliable model for preclinical efficacy verification of NK-related immunotherapy drugs.
Conclusion
To sum up, InnoModels' ADCC platform plays an important role in biomedical research with its diversified experimental service system, realistic simulation environment, high degree of customizability, and efficient data processing capabilities. In the future, as the biomedical field continues to develop, InnoModels' ADCC platform will continue to leverage its unique advantages to promote the progress and innovation of biomedical research. At the same time, the company will continue to be committed to innovation and development in the biomedical field to bring good news to more patients.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd